Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
677 days ago
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
932 days ago
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
959 days ago
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1031 days ago
Japan Producer Prices Slip 0.2% In June
Producer prices in Japan were down 0.2 percent on month in June, the Bank of Japan said on Thursday.
RTTNews
|
10 minutes ago
Continued Strength Predicted For Singapore Stock Market
The Singapore stock market has moved higher in three straight sessions, improving almost 45 points or 1.1 percent along the way. The Straits Times Index now rests just beneath the 4,060-point plateau and it's expected to open to the upside again on Thursday.
RTTNews
|
20 minutes ago
Malaysia Stock Market May Snap Losing Streak
The Malaysia stock market has moved lower in three straight sessions, slipping more than 20 points or 1.3 percent along the way. The Kuala Lumpur Composite Index now sits just beneath the 1,530-point plateau although it may stop the bleeding on Thursday.
RTTNews
|
50 minutes ago
Japan Bourse May Break Through 40,000-Point Barrier
The Japanese stock market has moved higher in back-to-back sessions, collecting more than 230 points or 0.6 percent in that span. The Nikkei 225 now sits just above the 39,820-point plateau and it's tipped to open in the green again on Thursday.
RTTNews
|
1h 5min ago
